Buscar
Congreso SOLACI
HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

Ver Categoría

Coronary disease

ABSORB III: after 3 Years, the Bioresorbable Scaffold is Still a Disappointment

Courtesy of the SBHCI. The 3-year outcomes of the ABSORB III trial, which randomized 2008 patients 2:1 to...
solaci -
Ver más
Coronary disease

Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique

 Courtesy of the SBHCI. The Absorb IV trial randomized 2604 patients in a 1:1 ratio to receive an Absorb everolimus-eluting...
solaci -
Ver más
Coronary disease

ABSORB II: No Benefits from Scaffolds After Complete Bioresorption

 Courtesy of the SBHCI. The ABSORB II study sought to assess the mechanical properties of everolimus-eluting bioresorbable scaffolds, such...
solaci -
Ver más
Coronary disease

2.0-mm DES for Very Small Vessels: Are They Viable?

The reference vessel diameter is a fundamental factor for restenosis after coronary angioplasty even with drug-eluting stents....
solaci -
Ver más
Coronary disease

Excellent Outcomes for the First Sirolimus Eluting Balloon Tested on Instent Restesosis

Much has been done since studies on conventional balloon angioplasty for BMS instent restenosis showed over 40% new revascularization.  Drug...
solaci -
Ver más
Coronary disease

Bioresorbable Scaffolds Must Not Be Chosen Over Current DES

Although there are 4 approved bioresorbable scaffolds (BRS) in Europe, experts suggest that current drug-eluting stents (DES)...
solaci -
Ver más
Coronary disease

With Absorb Out, New Resorbable Scaffolds Have Come onto the Market

By restoring vascular physiology and eliminating the inflammatory focus and the chance of fracture and neo atherosclerosis...
solaci -
Ver más
Coronary disease

These Are the Thrombosis Predictors for Absorb Bioresorbable Scaffolds

J Am Coll Cardiol Intv has recently published a special issue on bioresorbable scaffolds. Abbott's decision to...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad